حدد سهمًا أو عملة مشفرة في شريط البحث للحصول على ملخص
Neuca S.A.
NEUNEUCA S.A. engages in the wholesale distribution of pharmaceuticals in Poland. It operates through Wholesale Distribution of Medicines, Manufacture of Pharmaceuticals, Medical Operator, Clinical Trials, and Insurance Activities segments. The company owns and produces Rx, OTC medicines, dietary supplements, medical devices, dermocosmetics, hygiene products, personal protective equipment, as well as diagnostic and dressing materials under the Swiat Zdrowia, APTEO, GENOPTIM, CERA+ Solutions, and Kic Kic brand names to pharmacists, medical doctors, and patients. It provides medical care services, including prevention, diagnostics, treatment, and complementary services; and financing services, such as insurance, subscriptions, occupational medicine, preventive and medicine programmes, FFS, NFZ, public, private, and corporate payer services. In addition, the company offers TPA services, remote consultations, stationary visits, diagnostic tests, and occupational medicine services; operates a medical helpline and medical facilities; and offers medicine through apteline.pl, an e-commerce medical ordering site. Further, it engages in running clinical trials in the field of outsourcing clinical research and conducting clinical research centres; provision of insurance activities, including health insurance products. It also provides advertising and marketing services to pharmaceutical market entities; and logistics services for pharmaceutical manufacturers. The company was formerly known as Torfarm SA and changed its name to NEUCA S.A. in April 2010. NEUCA S.A. was founded in 1990 and is based in Torun, Poland. Address: Forteczna 35-37, Torun, Poland, 87-100
Analytics
سعر الهدف في وول ستريت
4 132.67 PLNنسبة السعر إلى الأرباح
22.0264العائد الربحي
1.88 %السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
الشخصيات الرئيسية NEU
تحليلات الأرباح NEU
نمو الأرباح على مدى 5 سنوات
103 %النمو المستمر
17 سنينمعدل الدفع 5 سنوات في المتوسط
35 %تاريخ الأرباح NEU
تقييم الأسهم NEU
المالية NEU
نتائج | 2019 | ديناميات |